| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Breast Neoplasms | 111 | 2024 | 20822 | 4.060 |
Why?
|
| Breast | 28 | 2024 | 1969 | 3.880 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 19 | 2023 | 949 | 3.020 |
Why?
|
| Breast Diseases | 18 | 2021 | 443 | 2.130 |
Why?
|
| Receptors, Estrogen | 37 | 2023 | 2187 | 1.920 |
Why?
|
| Receptors, Progesterone | 28 | 2021 | 1097 | 1.640 |
Why?
|
| Receptor, erbB-2 | 25 | 2023 | 2416 | 1.460 |
Why?
|
| Keratins | 6 | 2015 | 515 | 1.190 |
Why?
|
| Carcinoma in Situ | 8 | 2022 | 806 | 1.140 |
Why?
|
| Carcinoma, Lobular | 8 | 2022 | 484 | 1.130 |
Why?
|
| Carcinoma, Ductal, Breast | 11 | 2023 | 1101 | 0.920 |
Why?
|
| Hyperplasia | 7 | 2022 | 1185 | 0.860 |
Why?
|
| Reproductive History | 5 | 2021 | 209 | 0.830 |
Why?
|
| Precancerous Conditions | 9 | 2017 | 975 | 0.810 |
Why?
|
| Immunohistochemistry | 20 | 2021 | 11366 | 0.780 |
Why?
|
| Estrogen Receptor alpha | 4 | 2021 | 577 | 0.770 |
Why?
|
| Carcinoma, Papillary | 5 | 2022 | 783 | 0.730 |
Why?
|
| Tissue Array Analysis | 13 | 2021 | 553 | 0.610 |
Why?
|
| BRCA1 Protein | 2 | 2021 | 1149 | 0.570 |
Why?
|
| BRCA2 Protein | 1 | 2021 | 794 | 0.570 |
Why?
|
| Epithelium | 4 | 2021 | 1679 | 0.560 |
Why?
|
| Uveal Neoplasms | 3 | 2023 | 310 | 0.540 |
Why?
|
| Receptors, Androgen | 6 | 2019 | 1058 | 0.540 |
Why?
|
| Neoplasm Recurrence, Local | 14 | 2023 | 9239 | 0.530 |
Why?
|
| Biopsy | 14 | 2024 | 6756 | 0.510 |
Why?
|
| Female | 127 | 2024 | 380194 | 0.490 |
Why?
|
| Biopsy, Needle | 4 | 2009 | 1641 | 0.460 |
Why?
|
| Nomograms | 1 | 2015 | 228 | 0.450 |
Why?
|
| Genes, BRCA1 | 4 | 2010 | 781 | 0.410 |
Why?
|
| Neoplasm Invasiveness | 13 | 2016 | 3616 | 0.400 |
Why?
|
| Molecular Typing | 1 | 2011 | 106 | 0.390 |
Why?
|
| Muscle Cells | 2 | 2009 | 197 | 0.380 |
Why?
|
| Mammary Glands, Human | 4 | 2021 | 199 | 0.370 |
Why?
|
| Humans | 147 | 2024 | 744343 | 0.370 |
Why?
|
| Mammography | 11 | 2020 | 2476 | 0.370 |
Why?
|
| Epithelial Cells | 5 | 2010 | 3690 | 0.360 |
Why?
|
| Adult | 83 | 2023 | 214055 | 0.360 |
Why?
|
| Parity | 5 | 2021 | 929 | 0.350 |
Why?
|
| Case-Control Studies | 22 | 2021 | 21746 | 0.340 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2017 | 2942 | 0.300 |
Why?
|
| Middle Aged | 74 | 2022 | 213383 | 0.300 |
Why?
|
| Mucocele | 2 | 2022 | 49 | 0.290 |
Why?
|
| Risk Factors | 39 | 2021 | 72290 | 0.290 |
Why?
|
| Breast Cyst | 1 | 2006 | 8 | 0.290 |
Why?
|
| Agaricales | 1 | 2006 | 29 | 0.280 |
Why?
|
| Papilloma | 3 | 2015 | 148 | 0.270 |
Why?
|
| Myocytes, Smooth Muscle | 1 | 2010 | 687 | 0.270 |
Why?
|
| Vaginal Smears | 2 | 2001 | 511 | 0.270 |
Why?
|
| Prognosis | 20 | 2023 | 29063 | 0.260 |
Why?
|
| Neoadjuvant Therapy | 3 | 2020 | 2728 | 0.260 |
Why?
|
| Diagnosis, Differential | 4 | 2017 | 12959 | 0.250 |
Why?
|
| Uterine Cervical Dysplasia | 2 | 2001 | 387 | 0.250 |
Why?
|
| Mutation | 8 | 2023 | 29786 | 0.250 |
Why?
|
| Pathology | 1 | 2008 | 272 | 0.250 |
Why?
|
| Integrins | 5 | 2001 | 846 | 0.250 |
Why?
|
| Immunophenotyping | 4 | 2017 | 1880 | 0.250 |
Why?
|
| Laboratories | 1 | 2008 | 463 | 0.240 |
Why?
|
| Nurses | 11 | 2020 | 2461 | 0.240 |
Why?
|
| Prospective Studies | 24 | 2023 | 53288 | 0.230 |
Why?
|
| Gene Expression Profiling | 7 | 2019 | 9438 | 0.230 |
Why?
|
| Cadherins | 4 | 2022 | 907 | 0.220 |
Why?
|
| Polysaccharides | 2 | 2007 | 1053 | 0.220 |
Why?
|
| Fibrocystic Breast Disease | 2 | 2013 | 102 | 0.210 |
Why?
|
| Medical Records | 1 | 2008 | 1413 | 0.210 |
Why?
|
| Sclerosis | 2 | 2015 | 213 | 0.210 |
Why?
|
| Cohort Studies | 19 | 2021 | 40561 | 0.190 |
Why?
|
| Neoplasm Staging | 12 | 2016 | 11031 | 0.190 |
Why?
|
| Prolactin | 1 | 2023 | 669 | 0.190 |
Why?
|
| Alcohol Drinking | 5 | 2020 | 3966 | 0.190 |
Why?
|
| Gene Transfer Techniques | 6 | 2005 | 1224 | 0.180 |
Why?
|
| Melanoma | 3 | 2023 | 5510 | 0.180 |
Why?
|
| Diet, Vegetarian | 1 | 2021 | 174 | 0.180 |
Why?
|
| Doxorubicin | 1 | 2006 | 2234 | 0.180 |
Why?
|
| Odds Ratio | 8 | 2015 | 9849 | 0.180 |
Why?
|
| Osteoprotegerin | 1 | 2020 | 176 | 0.170 |
Why?
|
| Postmenopause | 6 | 2015 | 2461 | 0.170 |
Why?
|
| Specimen Handling | 1 | 2024 | 694 | 0.170 |
Why?
|
| Mastectomy, Segmental | 5 | 2022 | 956 | 0.170 |
Why?
|
| Erythrocyte Membrane | 1 | 2020 | 442 | 0.170 |
Why?
|
| Aged | 32 | 2023 | 163280 | 0.160 |
Why?
|
| Young Adult | 13 | 2021 | 56430 | 0.160 |
Why?
|
| Adenocarcinoma, Mucinous | 1 | 2022 | 506 | 0.160 |
Why?
|
| Gene Expression | 6 | 2015 | 7799 | 0.160 |
Why?
|
| Genetic Vectors | 5 | 2001 | 3420 | 0.150 |
Why?
|
| Recombinant Fusion Proteins | 2 | 2023 | 3772 | 0.150 |
Why?
|
| Stromal Cells | 4 | 2021 | 1355 | 0.150 |
Why?
|
| Adolescent | 19 | 2021 | 85781 | 0.150 |
Why?
|
| Age Factors | 6 | 2021 | 18370 | 0.150 |
Why?
|
| Keratin-5 | 3 | 2011 | 46 | 0.150 |
Why?
|
| Cervix Uteri | 1 | 2001 | 590 | 0.140 |
Why?
|
| Body Size | 2 | 2021 | 461 | 0.140 |
Why?
|
| Image Processing, Computer-Assisted | 3 | 2020 | 8949 | 0.140 |
Why?
|
| Body Height | 2 | 2020 | 1577 | 0.140 |
Why?
|
| Pathology, Surgical | 1 | 2017 | 155 | 0.140 |
Why?
|
| Uterine Cervical Neoplasms | 2 | 2001 | 2020 | 0.140 |
Why?
|
| Aged, 80 and over | 16 | 2020 | 57776 | 0.140 |
Why?
|
| Menarche | 2 | 2021 | 516 | 0.130 |
Why?
|
| Phenotype | 7 | 2020 | 16365 | 0.130 |
Why?
|
| Surgery, Computer-Assisted | 1 | 2004 | 1018 | 0.130 |
Why?
|
| Ki-67 Antigen | 1 | 2017 | 644 | 0.130 |
Why?
|
| Neoplasm, Residual | 1 | 2020 | 973 | 0.130 |
Why?
|
| Holistic Nursing | 1 | 2014 | 2 | 0.130 |
Why?
|
| Keratin-6 | 2 | 2011 | 18 | 0.130 |
Why?
|
| Risk | 6 | 2021 | 9687 | 0.120 |
Why?
|
| Immunoconjugates | 1 | 2022 | 901 | 0.120 |
Why?
|
| Metaplasia | 1 | 2015 | 313 | 0.120 |
Why?
|
| Isocitrate Dehydrogenase | 1 | 2020 | 871 | 0.120 |
Why?
|
| Genomics | 4 | 2023 | 5720 | 0.120 |
Why?
|
| Neoplasms, Second Primary | 1 | 2022 | 1061 | 0.120 |
Why?
|
| Apoptosis | 2 | 2007 | 9727 | 0.110 |
Why?
|
| Reproducibility of Results | 8 | 2021 | 19905 | 0.110 |
Why?
|
| Tumor Burden | 3 | 2016 | 1915 | 0.110 |
Why?
|
| Proportional Hazards Models | 10 | 2021 | 12354 | 0.110 |
Why?
|
| Predictive Value of Tests | 6 | 2021 | 15076 | 0.110 |
Why?
|
| Androgens | 1 | 2020 | 1281 | 0.110 |
Why?
|
| Insulin-Like Growth Factor I | 2 | 2012 | 2015 | 0.110 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 3 | 2 | 2012 | 424 | 0.110 |
Why?
|
| Polylysine | 3 | 2001 | 133 | 0.110 |
Why?
|
| Logistic Models | 6 | 2016 | 13408 | 0.110 |
Why?
|
| HLA-A Antigens | 2 | 2023 | 231 | 0.110 |
Why?
|
| Fatty Acids | 1 | 2020 | 1809 | 0.110 |
Why?
|
| Deoxyadenine Nucleotides | 1 | 2011 | 12 | 0.100 |
Why?
|
| Crotalid Venoms | 2 | 2001 | 28 | 0.100 |
Why?
|
| Genetic Predisposition to Disease | 3 | 2019 | 17446 | 0.100 |
Why?
|
| Tumor Cells, Cultured | 6 | 2012 | 6314 | 0.100 |
Why?
|
| Medical Oncology | 1 | 2023 | 2265 | 0.100 |
Why?
|
| Dinucleoside Phosphates | 1 | 2011 | 74 | 0.100 |
Why?
|
| Deoxyguanosine | 1 | 2011 | 84 | 0.100 |
Why?
|
| Inflammation Mediators | 1 | 2020 | 1889 | 0.100 |
Why?
|
| DNA Adducts | 1 | 2011 | 93 | 0.100 |
Why?
|
| Adiposity | 1 | 2020 | 1807 | 0.100 |
Why?
|
| Oligopeptides | 4 | 2012 | 1189 | 0.100 |
Why?
|
| Antineoplastic Agents | 3 | 2011 | 13695 | 0.090 |
Why?
|
| In Situ Hybridization | 1 | 2015 | 1950 | 0.090 |
Why?
|
| Follow-Up Studies | 10 | 2020 | 39050 | 0.090 |
Why?
|
| Vitamin D | 2 | 2016 | 3223 | 0.090 |
Why?
|
| Health Surveys | 2 | 2018 | 4037 | 0.090 |
Why?
|
| Interinstitutional Relations | 1 | 2012 | 241 | 0.090 |
Why?
|
| Breast Feeding | 1 | 2019 | 1338 | 0.090 |
Why?
|
| Receptors, Cell Surface | 2 | 2015 | 2866 | 0.090 |
Why?
|
| Risk Assessment | 10 | 2021 | 23338 | 0.090 |
Why?
|
| Aspirin | 3 | 2012 | 3282 | 0.090 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 3 | 2023 | 11524 | 0.090 |
Why?
|
| Organoplatinum Compounds | 1 | 2011 | 408 | 0.090 |
Why?
|
| Sexual Behavior | 1 | 2020 | 2057 | 0.090 |
Why?
|
| Testosterone | 1 | 2020 | 2420 | 0.090 |
Why?
|
| Carcinoma, Ductal | 1 | 2010 | 101 | 0.090 |
Why?
|
| Organ Transplantation | 1 | 2000 | 1139 | 0.090 |
Why?
|
| Cell Nucleus | 2 | 2011 | 2969 | 0.090 |
Why?
|
| Fibroadenoma | 1 | 2009 | 43 | 0.090 |
Why?
|
| United States | 15 | 2021 | 69872 | 0.080 |
Why?
|
| Mucins | 2 | 2022 | 564 | 0.080 |
Why?
|
| Estrogen Receptor beta | 1 | 2009 | 175 | 0.080 |
Why?
|
| Mastectomy | 3 | 2022 | 1793 | 0.080 |
Why?
|
| Insulin-Like Growth Factor Binding Proteins | 1 | 2010 | 216 | 0.080 |
Why?
|
| Cyclooxygenase 2 | 1 | 2011 | 611 | 0.080 |
Why?
|
| Receptor, IGF Type 1 | 1 | 2011 | 390 | 0.080 |
Why?
|
| Observer Variation | 3 | 2021 | 2593 | 0.080 |
Why?
|
| Acetaminophen | 1 | 2012 | 545 | 0.080 |
Why?
|
| Endometriosis | 1 | 2016 | 839 | 0.080 |
Why?
|
| Bone Resorption | 1 | 2012 | 723 | 0.080 |
Why?
|
| Cooperative Behavior | 2 | 2014 | 1504 | 0.080 |
Why?
|
| Neoplasms, Hormone-Dependent | 1 | 2011 | 415 | 0.080 |
Why?
|
| Time Factors | 9 | 2013 | 40075 | 0.080 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 2 | 2022 | 890 | 0.080 |
Why?
|
| Nuts | 1 | 2010 | 257 | 0.080 |
Why?
|
| Mastectomy, Simple | 1 | 2007 | 24 | 0.080 |
Why?
|
| Cathepsins | 1 | 2008 | 241 | 0.080 |
Why?
|
| Heat-Shock Proteins | 1 | 2011 | 822 | 0.080 |
Why?
|
| Basidiomycota | 1 | 2007 | 17 | 0.070 |
Why?
|
| Gene Expression Regulation, Neoplastic | 3 | 2019 | 8428 | 0.070 |
Why?
|
| Drug Screening Assays, Antitumor | 2 | 2007 | 730 | 0.070 |
Why?
|
| Seroma | 1 | 2007 | 71 | 0.070 |
Why?
|
| Heterozygote | 2 | 2012 | 2804 | 0.070 |
Why?
|
| Carcinoma, Large Cell | 1 | 2007 | 113 | 0.070 |
Why?
|
| Amino Acid Chloromethyl Ketones | 1 | 2006 | 68 | 0.070 |
Why?
|
| Exercise | 2 | 2015 | 5615 | 0.070 |
Why?
|
| Chemokines, CXC | 1 | 2008 | 422 | 0.070 |
Why?
|
| Prostatic Neoplasms | 2 | 2007 | 11124 | 0.070 |
Why?
|
| Pregnancy | 6 | 2019 | 29144 | 0.070 |
Why?
|
| Diet | 3 | 2014 | 7939 | 0.070 |
Why?
|
| Keratin-14 | 1 | 2006 | 57 | 0.070 |
Why?
|
| BH3 Interacting Domain Death Agonist Protein | 1 | 2006 | 92 | 0.070 |
Why?
|
| MAP Kinase Kinase 4 | 1 | 2006 | 148 | 0.070 |
Why?
|
| Codon, Nonsense | 1 | 2007 | 281 | 0.070 |
Why?
|
| Dietary Fiber | 1 | 2010 | 760 | 0.070 |
Why?
|
| Bile Canaliculi | 1 | 2005 | 11 | 0.070 |
Why?
|
| Interdisciplinary Communication | 1 | 2012 | 950 | 0.070 |
Why?
|
| Lysine | 3 | 2014 | 1007 | 0.070 |
Why?
|
| Multivariate Analysis | 6 | 2019 | 12245 | 0.070 |
Why?
|
| Premenopause | 3 | 2020 | 1033 | 0.060 |
Why?
|
| Folic Acid | 1 | 2012 | 1300 | 0.060 |
Why?
|
| Osteogenesis | 1 | 2012 | 1299 | 0.060 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2001 | 4034 | 0.060 |
Why?
|
| Psychometrics | 1 | 2014 | 3002 | 0.060 |
Why?
|
| Neoplastic Syndromes, Hereditary | 1 | 2007 | 241 | 0.060 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2015 | 2849 | 0.060 |
Why?
|
| Tamoxifen | 2 | 2009 | 981 | 0.060 |
Why?
|
| Carcinoid Tumor | 1 | 2006 | 235 | 0.060 |
Why?
|
| Neuroanatomy | 2 | 2001 | 66 | 0.060 |
Why?
|
| Antineoplastic Agents, Hormonal | 3 | 2011 | 1524 | 0.060 |
Why?
|
| Managed Care Programs | 1 | 2010 | 950 | 0.060 |
Why?
|
| Transfection | 3 | 2001 | 5892 | 0.060 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2017 | 3327 | 0.060 |
Why?
|
| Muscle, Smooth, Vascular | 2 | 2001 | 1504 | 0.060 |
Why?
|
| Neoplastic Processes | 1 | 2023 | 35 | 0.060 |
Why?
|
| Lymphatic Metastasis | 4 | 2019 | 2924 | 0.060 |
Why?
|
| Histones | 1 | 2014 | 2599 | 0.060 |
Why?
|
| Treatment Outcome | 8 | 2020 | 63114 | 0.060 |
Why?
|
| Patient-Centered Care | 1 | 2014 | 1439 | 0.060 |
Why?
|
| Retrospective Studies | 11 | 2024 | 77449 | 0.060 |
Why?
|
| Receptors, Antigen, T-Cell | 2 | 2023 | 2540 | 0.060 |
Why?
|
| Pathology, Clinical | 2 | 2006 | 368 | 0.060 |
Why?
|
| Polymerase Chain Reaction | 2 | 2010 | 6171 | 0.060 |
Why?
|
| Caspases | 1 | 2006 | 928 | 0.060 |
Why?
|
| Early Detection of Cancer | 2 | 2014 | 3086 | 0.050 |
Why?
|
| Neoplasm Proteins | 2 | 2013 | 3703 | 0.050 |
Why?
|
| Disease Progression | 2 | 2017 | 13284 | 0.050 |
Why?
|
| Tight Junctions | 1 | 2005 | 311 | 0.050 |
Why?
|
| Incidence | 7 | 2016 | 20947 | 0.050 |
Why?
|
| Dose-Response Relationship, Drug | 4 | 2012 | 10943 | 0.050 |
Why?
|
| STAT5 Transcription Factor | 1 | 2023 | 259 | 0.050 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2012 | 2282 | 0.050 |
Why?
|
| Dissection | 1 | 2024 | 295 | 0.050 |
Why?
|
| Cation Exchange Resins | 1 | 2001 | 21 | 0.050 |
Why?
|
| Hemagglutinins, Viral | 1 | 2001 | 67 | 0.050 |
Why?
|
| Drug Synergism | 1 | 2006 | 1792 | 0.050 |
Why?
|
| Proto-Oncogene Proteins c-kit | 1 | 2006 | 776 | 0.050 |
Why?
|
| Terminology as Topic | 1 | 2009 | 1547 | 0.050 |
Why?
|
| Stereotaxic Techniques | 1 | 2004 | 536 | 0.050 |
Why?
|
| Hemagglutinins | 1 | 2001 | 117 | 0.050 |
Why?
|
| Anatomy, Artistic | 1 | 2001 | 52 | 0.050 |
Why?
|
| Family Health | 1 | 2006 | 1282 | 0.050 |
Why?
|
| Anatomy, Cross-Sectional | 1 | 2001 | 141 | 0.050 |
Why?
|
| DNA Repair | 1 | 2010 | 2046 | 0.050 |
Why?
|
| Cytodiagnosis | 1 | 2005 | 435 | 0.050 |
Why?
|
| Patient Selection | 2 | 2012 | 4215 | 0.050 |
Why?
|
| Medical Illustration | 1 | 2001 | 133 | 0.050 |
Why?
|
| Respiratory Muscles | 1 | 2001 | 139 | 0.050 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2015 | 3143 | 0.050 |
Why?
|
| Staining and Labeling | 1 | 2005 | 1100 | 0.050 |
Why?
|
| Calcinosis | 1 | 2009 | 1499 | 0.050 |
Why?
|
| Chloroquine | 1 | 2001 | 280 | 0.050 |
Why?
|
| Carbonated Beverages | 1 | 2021 | 214 | 0.050 |
Why?
|
| Genome-Wide Association Study | 1 | 2019 | 12261 | 0.040 |
Why?
|
| Monosomy | 1 | 1999 | 54 | 0.040 |
Why?
|
| Neoplasms | 3 | 2024 | 21683 | 0.040 |
Why?
|
| Receptors, Antigen, T-Cell, alpha-beta | 1 | 2023 | 805 | 0.040 |
Why?
|
| Core Binding Factor Alpha 2 Subunit | 1 | 2022 | 345 | 0.040 |
Why?
|
| Body Mass Index | 3 | 2021 | 12720 | 0.040 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2011 | 3508 | 0.040 |
Why?
|
| Immunoenzyme Techniques | 2 | 2015 | 1799 | 0.040 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2014 | 3923 | 0.040 |
Why?
|
| Germ-Line Mutation | 1 | 2007 | 1788 | 0.040 |
Why?
|
| Reflex | 1 | 2001 | 365 | 0.040 |
Why?
|
| Kaplan-Meier Estimate | 3 | 2019 | 6538 | 0.040 |
Why?
|
| Kidney Neoplasms | 1 | 2015 | 4262 | 0.040 |
Why?
|
| Carcinoma | 1 | 2010 | 2375 | 0.040 |
Why?
|
| Calcium | 1 | 2012 | 5756 | 0.040 |
Why?
|
| Elasticity | 1 | 2021 | 657 | 0.040 |
Why?
|
| Quality of Health Care | 1 | 2014 | 4371 | 0.040 |
Why?
|
| Sweetening Agents | 1 | 2021 | 296 | 0.040 |
Why?
|
| Patient Compliance | 1 | 2009 | 2684 | 0.040 |
Why?
|
| Women's Health | 1 | 2008 | 2034 | 0.040 |
Why?
|
| Peptides | 2 | 2001 | 4409 | 0.040 |
Why?
|
| Germ Cells | 1 | 2022 | 631 | 0.040 |
Why?
|
| Sex Reassignment Surgery | 1 | 2020 | 130 | 0.040 |
Why?
|
| Chromosomes, Human, Pair 9 | 1 | 1999 | 535 | 0.040 |
Why?
|
| Practice Guidelines as Topic | 1 | 2015 | 7279 | 0.040 |
Why?
|
| Organoids | 1 | 2023 | 701 | 0.040 |
Why?
|
| Algorithms | 2 | 2016 | 13881 | 0.040 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 2 | 2016 | 3920 | 0.040 |
Why?
|
| Sensitivity and Specificity | 2 | 2004 | 14722 | 0.040 |
Why?
|
| DNA | 2 | 2022 | 7301 | 0.040 |
Why?
|
| Respiratory Mechanics | 1 | 2001 | 686 | 0.040 |
Why?
|
| Retinoid X Receptors | 1 | 2016 | 93 | 0.040 |
Why?
|
| Tumor Microenvironment | 2 | 2023 | 3586 | 0.040 |
Why?
|
| Cold Temperature | 1 | 2000 | 772 | 0.040 |
Why?
|
| Animals | 9 | 2017 | 168757 | 0.030 |
Why?
|
| Cell Polarity | 1 | 2020 | 645 | 0.030 |
Why?
|
| Chemotherapy, Adjuvant | 3 | 2011 | 3479 | 0.030 |
Why?
|
| Huntington Disease | 1 | 2003 | 1124 | 0.030 |
Why?
|
| Automation, Laboratory | 1 | 2016 | 101 | 0.030 |
Why?
|
| Databases, Factual | 2 | 2001 | 7729 | 0.030 |
Why?
|
| Ultrasonography | 1 | 2009 | 5985 | 0.030 |
Why?
|
| Prenatal Diagnosis | 1 | 2003 | 1236 | 0.030 |
Why?
|
| Anthropometry | 1 | 2020 | 1350 | 0.030 |
Why?
|
| Beverages | 1 | 2021 | 820 | 0.030 |
Why?
|
| Radioimmunoassay | 1 | 2016 | 919 | 0.030 |
Why?
|
| Oncogene Protein v-akt | 1 | 2015 | 135 | 0.030 |
Why?
|
| Colposcopy | 1 | 1996 | 144 | 0.030 |
Why?
|
| Transcription Factors | 1 | 2015 | 12208 | 0.030 |
Why?
|
| Hepatocyte Nuclear Factor 3-alpha | 1 | 2015 | 170 | 0.030 |
Why?
|
| Cell Proliferation | 2 | 2012 | 10481 | 0.030 |
Why?
|
| Lymph Nodes | 2 | 2019 | 3474 | 0.030 |
Why?
|
| Genetic Variation | 1 | 2010 | 6544 | 0.030 |
Why?
|
| Multiple Myeloma | 1 | 2012 | 5181 | 0.030 |
Why?
|
| Case Management | 1 | 1996 | 286 | 0.030 |
Why?
|
| Europe | 1 | 2021 | 3339 | 0.030 |
Why?
|
| Viral Proteins | 1 | 2001 | 1900 | 0.030 |
Why?
|
| Population Surveillance | 2 | 2015 | 2616 | 0.030 |
Why?
|
| Thienamycins | 1 | 1993 | 28 | 0.030 |
Why?
|
| Receptors, Calcitriol | 1 | 2016 | 350 | 0.030 |
Why?
|
| Registries | 1 | 2009 | 8089 | 0.030 |
Why?
|
| Nursing Staff | 1 | 2015 | 129 | 0.030 |
Why?
|
| DNA Copy Number Variations | 1 | 2022 | 1941 | 0.030 |
Why?
|
| Ontario | 1 | 2014 | 383 | 0.030 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 1999 | 2649 | 0.030 |
Why?
|
| Cell Line, Tumor | 2 | 2007 | 16689 | 0.030 |
Why?
|
| Lipid Metabolism | 1 | 2001 | 1889 | 0.030 |
Why?
|
| RNA, Messenger | 3 | 2013 | 13033 | 0.030 |
Why?
|
| Menopause | 1 | 2021 | 1626 | 0.030 |
Why?
|
| Fibroblasts | 1 | 2023 | 4161 | 0.030 |
Why?
|
| Radiotherapy, Adjuvant | 2 | 2009 | 1770 | 0.030 |
Why?
|
| Gram-Positive Bacteria | 1 | 1993 | 184 | 0.030 |
Why?
|
| Combined Modality Therapy | 2 | 2020 | 8642 | 0.030 |
Why?
|
| Male | 11 | 2020 | 350118 | 0.030 |
Why?
|
| Liver | 2 | 2005 | 7474 | 0.030 |
Why?
|
| Peptide Fragments | 2 | 2001 | 5097 | 0.030 |
Why?
|
| Epoxy Compounds | 1 | 2012 | 136 | 0.030 |
Why?
|
| Analysis of Variance | 1 | 2021 | 6365 | 0.030 |
Why?
|
| Gram-Negative Bacteria | 1 | 1993 | 270 | 0.030 |
Why?
|
| Calcification, Physiologic | 1 | 2012 | 169 | 0.030 |
Why?
|
| Students, Nursing | 1 | 2012 | 45 | 0.030 |
Why?
|
| Neovascularization, Pathologic | 1 | 2022 | 2635 | 0.030 |
Why?
|
| Micronutrients | 1 | 2014 | 375 | 0.030 |
Why?
|
| Survival Rate | 2 | 2020 | 12788 | 0.030 |
Why?
|
| Methylation | 1 | 2014 | 1106 | 0.030 |
Why?
|
| Receptor, Insulin | 1 | 2015 | 846 | 0.020 |
Why?
|
| Prevalence | 1 | 2008 | 15226 | 0.020 |
Why?
|
| Therapeutic Irrigation | 2 | 2005 | 301 | 0.020 |
Why?
|
| Nurse Practitioners | 1 | 2014 | 270 | 0.020 |
Why?
|
| Epidemiologic Studies | 1 | 2014 | 676 | 0.020 |
Why?
|
| Nursing Staff, Hospital | 1 | 2014 | 346 | 0.020 |
Why?
|
| Graft Rejection | 2 | 2001 | 4397 | 0.020 |
Why?
|
| Poly(ADP-ribose) Polymerases | 1 | 2012 | 440 | 0.020 |
Why?
|
| HCT116 Cells | 1 | 2011 | 408 | 0.020 |
Why?
|
| Nutritional Requirements | 1 | 2012 | 286 | 0.020 |
Why?
|
| Allied Health Personnel | 1 | 2012 | 162 | 0.020 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2023 | 4479 | 0.020 |
Why?
|
| Databases, Genetic | 1 | 2016 | 1783 | 0.020 |
Why?
|
| Thrombin | 1 | 1992 | 598 | 0.020 |
Why?
|
| Adipose Tissue | 1 | 2021 | 3279 | 0.020 |
Why?
|
| Pyrroles | 1 | 2015 | 1146 | 0.020 |
Why?
|
| Cathepsin K | 1 | 2008 | 68 | 0.020 |
Why?
|
| ROC Curve | 1 | 2016 | 3527 | 0.020 |
Why?
|
| Medical Audit | 1 | 2010 | 467 | 0.020 |
Why?
|
| Self Report | 1 | 2020 | 3558 | 0.020 |
Why?
|
| Osteoclasts | 1 | 2012 | 729 | 0.020 |
Why?
|
| Necrosis | 1 | 2012 | 1643 | 0.020 |
Why?
|
| Carrier Proteins | 1 | 2001 | 5021 | 0.020 |
Why?
|
| Biopsy, Fine-Needle | 1 | 2013 | 1094 | 0.020 |
Why?
|
| Alleles | 1 | 2019 | 6933 | 0.020 |
Why?
|
| Boronic Acids | 1 | 2012 | 965 | 0.020 |
Why?
|
| Program Development | 1 | 2014 | 1316 | 0.020 |
Why?
|
| Rabbits | 3 | 2001 | 4894 | 0.020 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2011 | 1572 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 4 | 2009 | 35421 | 0.020 |
Why?
|
| Mice, Inbred NOD | 1 | 2012 | 1878 | 0.020 |
Why?
|
| Microarray Analysis | 1 | 2010 | 767 | 0.020 |
Why?
|
| Genes, Reporter | 2 | 2001 | 1547 | 0.020 |
Why?
|
| Caspase 2 | 1 | 2007 | 27 | 0.020 |
Why?
|
| Age Distribution | 1 | 2013 | 2902 | 0.020 |
Why?
|
| Indoles | 1 | 2015 | 1839 | 0.020 |
Why?
|
| Personal Satisfaction | 1 | 2012 | 643 | 0.020 |
Why?
|
| SEER Program | 1 | 2012 | 1508 | 0.020 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 1999 | 2245 | 0.020 |
Why?
|
| Mice, SCID | 1 | 2012 | 2716 | 0.020 |
Why?
|
| Diagnostic Errors | 1 | 2014 | 1257 | 0.020 |
Why?
|
| Estrogen Replacement Therapy | 1 | 2013 | 1203 | 0.020 |
Why?
|
| Heart Transplantation | 1 | 2000 | 3110 | 0.020 |
Why?
|
| Caspase 8 | 1 | 2007 | 195 | 0.020 |
Why?
|
| Osteoblasts | 1 | 2012 | 1166 | 0.020 |
Why?
|
| Dietary Fats | 1 | 2014 | 2017 | 0.020 |
Why?
|
| Pyrazines | 1 | 2012 | 1230 | 0.020 |
Why?
|
| Cytoplasm | 1 | 2011 | 1539 | 0.020 |
Why?
|
| California | 1 | 2010 | 1402 | 0.020 |
Why?
|
| Brain Mapping | 1 | 2001 | 6669 | 0.020 |
Why?
|
| Polymorphism, Single Nucleotide | 2 | 2019 | 15519 | 0.020 |
Why?
|
| Fibrosis | 1 | 2012 | 2029 | 0.020 |
Why?
|
| Egtazic Acid | 1 | 2005 | 173 | 0.020 |
Why?
|
| Interprofessional Relations | 1 | 2012 | 1011 | 0.020 |
Why?
|
| Cluster Analysis | 1 | 2012 | 2715 | 0.020 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2011 | 1157 | 0.020 |
Why?
|
| Models, Molecular | 1 | 2015 | 5456 | 0.020 |
Why?
|
| Infusions, Parenteral | 1 | 2005 | 419 | 0.020 |
Why?
|
| Longitudinal Studies | 1 | 2021 | 13989 | 0.020 |
Why?
|
| Disease-Free Survival | 1 | 2015 | 6895 | 0.020 |
Why?
|
| Mass Screening | 1 | 2001 | 5255 | 0.020 |
Why?
|
| DNA Methylation | 2 | 2010 | 4286 | 0.020 |
Why?
|
| Loss of Heterozygosity | 1 | 2007 | 684 | 0.020 |
Why?
|
| Antigens, CD | 1 | 2015 | 4026 | 0.020 |
Why?
|
| Motor Activity | 1 | 2015 | 2714 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2012 | 4751 | 0.020 |
Why?
|
| Brain | 2 | 2001 | 26385 | 0.020 |
Why?
|
| Genotype | 1 | 2019 | 12951 | 0.020 |
Why?
|
| Caspase 3 | 1 | 2007 | 758 | 0.020 |
Why?
|
| Administration, Oral | 1 | 2012 | 3913 | 0.020 |
Why?
|
| Blotting, Western | 1 | 2012 | 5179 | 0.020 |
Why?
|
| Laparoscopy | 1 | 2016 | 2151 | 0.020 |
Why?
|
| Body Weight | 1 | 2015 | 4669 | 0.010 |
Why?
|
| Cell Culture Techniques | 1 | 2011 | 1678 | 0.010 |
Why?
|
| Membrane Proteins | 1 | 2001 | 7880 | 0.010 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2012 | 941 | 0.010 |
Why?
|
| Chelating Agents | 1 | 2005 | 380 | 0.010 |
Why?
|
| Genetic Heterogeneity | 1 | 2007 | 733 | 0.010 |
Why?
|
| Rats, Inbred Lew | 1 | 2005 | 1162 | 0.010 |
Why?
|
| Haplotypes | 1 | 2010 | 2779 | 0.010 |
Why?
|
| Permeability | 1 | 2005 | 738 | 0.010 |
Why?
|
| Life Style | 1 | 2014 | 3835 | 0.010 |
Why?
|
| Thrombolytic Therapy | 1 | 1992 | 2161 | 0.010 |
Why?
|
| DNA-Binding Proteins | 1 | 2000 | 9648 | 0.010 |
Why?
|
| Sentinel Lymph Node Biopsy | 1 | 2007 | 709 | 0.010 |
Why?
|
| Crotalus | 1 | 2001 | 7 | 0.010 |
Why?
|
| Lung | 1 | 2001 | 9856 | 0.010 |
Why?
|
| Learning | 1 | 2012 | 1713 | 0.010 |
Why?
|
| Rats | 3 | 2005 | 24260 | 0.010 |
Why?
|
| Bone Marrow | 1 | 2012 | 2948 | 0.010 |
Why?
|
| Drug Administration Routes | 1 | 2001 | 153 | 0.010 |
Why?
|
| Trinucleotide Repeat Expansion | 1 | 2003 | 243 | 0.010 |
Why?
|
| Genes, BRCA2 | 1 | 2005 | 618 | 0.010 |
Why?
|
| Gold | 1 | 2005 | 484 | 0.010 |
Why?
|
| Factor IX | 1 | 2001 | 77 | 0.010 |
Why?
|
| Blood Platelets | 1 | 1992 | 2508 | 0.010 |
Why?
|
| Lac Operon | 1 | 2001 | 238 | 0.010 |
Why?
|
| Phrenic Nerve | 1 | 2001 | 79 | 0.010 |
Why?
|
| Particle Size | 1 | 2005 | 1642 | 0.010 |
Why?
|
| Cell Membrane | 1 | 2011 | 3748 | 0.010 |
Why?
|
| Health Personnel | 1 | 2014 | 3218 | 0.010 |
Why?
|
| Inhalation | 1 | 2001 | 143 | 0.010 |
Why?
|
| Child | 2 | 2020 | 77709 | 0.010 |
Why?
|
| Saline Solution, Hypertonic | 1 | 2001 | 110 | 0.010 |
Why?
|
| Rats, Inbred Strains | 1 | 2001 | 2186 | 0.010 |
Why?
|
| Bile Ducts | 1 | 2001 | 284 | 0.010 |
Why?
|
| Abdominal Muscles | 1 | 2001 | 166 | 0.010 |
Why?
|
| Binding, Competitive | 1 | 2001 | 1157 | 0.010 |
Why?
|
| Nanostructures | 1 | 2005 | 551 | 0.010 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2010 | 2948 | 0.010 |
Why?
|
| Regression Analysis | 1 | 2010 | 6459 | 0.010 |
Why?
|
| beta-Galactosidase | 1 | 2001 | 573 | 0.010 |
Why?
|
| Cross-Sectional Studies | 2 | 2012 | 25043 | 0.010 |
Why?
|
| Catheterization | 1 | 2005 | 1470 | 0.010 |
Why?
|
| Pedigree | 1 | 2007 | 4644 | 0.010 |
Why?
|
| Portal Vein | 1 | 2001 | 437 | 0.010 |
Why?
|
| Cell Line | 2 | 2005 | 15997 | 0.010 |
Why?
|
| Luciferases | 1 | 2001 | 733 | 0.010 |
Why?
|
| Amino Acid Motifs | 1 | 2001 | 936 | 0.010 |
Why?
|
| Recurrence | 1 | 2010 | 8340 | 0.010 |
Why?
|
| Survival Analysis | 1 | 2011 | 10252 | 0.010 |
Why?
|
| Vagus Nerve | 1 | 2001 | 438 | 0.010 |
Why?
|
| Child, Preschool | 1 | 2020 | 41006 | 0.010 |
Why?
|
| Stomach Neoplasms | 1 | 2007 | 1333 | 0.010 |
Why?
|
| Attitude of Health Personnel | 1 | 2012 | 3843 | 0.010 |
Why?
|
| Canada | 1 | 2003 | 2065 | 0.010 |
Why?
|
| Communication | 1 | 2012 | 3749 | 0.010 |
Why?
|
| Up-Regulation | 1 | 2007 | 4217 | 0.010 |
Why?
|
| Hydrogen Peroxide | 1 | 2001 | 731 | 0.010 |
Why?
|
| Massachusetts | 1 | 2010 | 8663 | 0.010 |
Why?
|
| Axilla | 1 | 1998 | 595 | 0.010 |
Why?
|
| Age of Onset | 1 | 2003 | 3271 | 0.010 |
Why?
|
| Probability | 1 | 2001 | 2505 | 0.010 |
Why?
|
| Electromyography | 1 | 2001 | 1379 | 0.010 |
Why?
|
| Chronic Disease | 2 | 2001 | 9146 | 0.010 |
Why?
|
| Research Design | 1 | 2011 | 5987 | 0.010 |
Why?
|
| Cell Differentiation | 1 | 2012 | 11483 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 1 | 2012 | 21827 | 0.010 |
Why?
|
| Imipenem | 1 | 1993 | 38 | 0.010 |
Why?
|
| Ligands | 1 | 2001 | 3282 | 0.010 |
Why?
|
| Binding Sites | 1 | 2001 | 6114 | 0.010 |
Why?
|
| Methicillin Resistance | 1 | 1993 | 198 | 0.010 |
Why?
|
| Obesity | 1 | 2015 | 12745 | 0.010 |
Why?
|
| Mice, Inbred BALB C | 1 | 2001 | 6386 | 0.010 |
Why?
|
| Transplantation, Homologous | 1 | 2001 | 4776 | 0.010 |
Why?
|
| Pilot Projects | 1 | 2005 | 8324 | 0.010 |
Why?
|
| Gram-Negative Bacterial Infections | 1 | 1993 | 232 | 0.010 |
Why?
|
| Hirudins | 1 | 1992 | 183 | 0.010 |
Why?
|
| Mice | 2 | 2012 | 81183 | 0.010 |
Why?
|
| Gram-Positive Bacterial Infections | 1 | 1993 | 341 | 0.010 |
Why?
|
| Image Enhancement | 1 | 2001 | 2921 | 0.010 |
Why?
|
| Lipids | 1 | 2001 | 3305 | 0.010 |
Why?
|
| Respiration, Artificial | 1 | 2001 | 2569 | 0.010 |
Why?
|
| Amino Acid Sequence | 1 | 2001 | 13815 | 0.010 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2001 | 2214 | 0.010 |
Why?
|
| Platelet Aggregation | 1 | 1992 | 798 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 2001 | 18111 | 0.010 |
Why?
|
| Platelet Activation | 1 | 1992 | 673 | 0.000 |
Why?
|
| Neoplasm Metastasis | 1 | 1999 | 4851 | 0.000 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2001 | 4042 | 0.000 |
Why?
|
| Microbial Sensitivity Tests | 1 | 1993 | 1877 | 0.000 |
Why?
|
| Models, Statistical | 1 | 2001 | 5102 | 0.000 |
Why?
|
| Tissue Plasminogen Activator | 1 | 1992 | 1261 | 0.000 |
Why?
|
| Heparin | 1 | 1992 | 1637 | 0.000 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2006 | 20129 | 0.000 |
Why?
|
| Schizophrenia | 1 | 2001 | 6882 | 0.000 |
Why?
|
| Anti-Bacterial Agents | 1 | 1993 | 7181 | 0.000 |
Why?
|